-
Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting
•
China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study for its IBI351 monotherapy in advanced solid tumors at the American Association for Cancer Research (AACR) annual meeting. IBI351: A KRAS G12C Inhibitor Under AssessmentIBI351 (GFH925), a KRAS G12C inhibitor originated by GenFleet Therapeutics Inc.,…
-
China Resources Biopharmaceutical Partners with Hefei Institute and Afana Bio for Joint Lab
•
China Resources Biopharmaceutical Co., Ltd has announced a strategic partnership with the Hefei Comprehensive National Science Center’s Institute of Health and Medicine and Hefei Afana Biotechnology Co., Ltd to establish a joint laboratory. The new lab will concentrate on advancing biotechnology innovation and translational medicine. Leveraging Core Competencies for Nucleic…
-
XZenith Biopharm Completes Enrollment in Phase II Study for Proton Pump Inhibitor
•
XZenith Biopharm, a Chinese company with minority ownership by Sihuan Pharma, has completed patient enrollment in a Phase II clinical study for its in-house developed proton pump inhibitor (PPI). The study focuses on the treatment of adult reflux esophagitis (RE) and the control of related symptoms, such as acid reflux,…
-
Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting
•
China-based Adagene Inc. (NASDAQ: ADAG) has announced interim results from its combination dose escalation studies of the masked, anti-CTLA-4 SAFEbody, ADG126, at the AACR Annual Meeting in Orlando, Florida, from April 14-19, 2023. The studies include a Phase Ib/II study for ADG126 as a monotherapy and in combination with toripalimab…
-
BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination
•
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) and SpringWorks Therapeutics Inc., (NASDAQ: SWTX) have published the latest data from a Phase Ib clinical study assessing the combination of BeiGene’s RAF dimer inhibitor lifirafenib and SpringWorks’ MEK inhibitor mirdametinib in advanced or refractory solid tumors carrying RAS mutations, RAF mutations,…
-
HanchorBio Receives FDA Approval for Multi-Region Clinical Study of HCB101 Fusion Protein
•
Taiwan-based HanchorBio has announced receiving the green light from the US FDA to conduct a multi-region, multi-center clinical study for its innovative fusion protein, HCB101. The non-blind, dose exploration first-in-human trial will be conducted in the US and Taiwan, focusing on assessing the safety, tolerability, pharmacokinetics, and preliminary clinical anti-tumor…
-
Hainan’s Boao Lecheng Partners with Sonova to Advance Hearing Health Solutions in China
•
The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has struck a strategic partnership with Swiss company Sonova, marking a Sino-Swiss collaboration aimed at enhancing the introduction and implementation of innovative hearing health solutions in China. The partnership focuses on jointly promoting the introduction of cutting-edge hearing aids and…
-
Nanjing Chamlion Laser Technology Secures RMB 236 Million in Series B Financing for Dental 3D Printing
•
Nanjing Chamlion Laser Technology Co., Ltd, a leading provider of dental metal 3D printing solutions in China, has reportedly raised RMB 236 million (USD 34.3 million) in a Series B financing round. The round was led by 3H Health Investment, with participation from Vertex Ventures and ZhenCheng Capital. The funds…
-
HutchMed’s Elunate Receives NMPA Review for Second-Line Gastric Cancer Treatment
•
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that the National Medical Products Administration (NMPA) has accepted a market approval filing for the VEGFR inhibitor Elunate (fruquintinib) in China. The filing focuses on the use of Elunate in combination with paclitaxel as a second-line treatment for advanced gastric or gastroesophageal…
-
HuidaGene Receives CDE IND Approval for Ophthalmology Gene Therapy HG004
•
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) in China for its ophthalmology gene therapy, HG004. This gene replacement therapy drug utilizes a recombinant non-adeno-associated virus serotype 2 (non-AAV2) vector to deliver a functional human RPE65 gene…
-
CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma
•
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the Phase I clinical study for its C-CAR031 at the American Association for Cancer Research (AACR) annual meeting 2023. The open Phase I study was designed to assess the safety and tolerability of C-CAR031, featuring a…
-
CanSino Biologics Reports 2022 Revenue Drop and Increased Losses Amid COVID-19 Vaccine Market Shifts
•
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has released its 2022 financial report, recording RMB 1.031 billion (USD 149.9 million) in revenue, marking a 76.02% year-on-year (YOY) decrease, and reporting RMB 187 million (USD 27.19 million) in losses compared to RMB 3 billion (USD 436 million) in gross profits…
-
PackGene Secures Series C Financing to Boost AAV Innovation and Global Expansion
•
China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing hundreds of millions of renminbi. The round was led by a consortium of investors including GDD Industry Fund, Guangzhou Xinxing Industry Development Fund, Yuegang Capital, Sanmei Investment, and Guangzhou Guoju Venture Capital, along with an…
-
Bioworkshops Secures RMB 100 Million in Series A Financing for Biologic Drug Development
•
Bioworkshops, a Contract Development and Manufacturing Organization (CDMO) based in Suzhou and specializing in biologic drugs, has announced the completion of a Series A financing round worth RMB 100 million (USD 14.5 million). The investment was led by Jiangsu Tech Industry Investment Co., Ltd. Company Background and ServicesFounded in 2019,…
-
Sinovation Medical’s SinoLITT System and Fiber Kit Gain NMPA Approval for Epilepsy Treatment
•
Sinovation (Beijing) Medical Technology Co., Ltd has announced that its in-house developed magnetic resonance monitoring semiconductor laser therapy equipment, the SinoLITT System, and disposable laser fiber kit have been approved by the National Medical Products Administration (NMPA) for use in laser treatment of local lesions in patients with drug-resistant epilepsy,…
-
Merck and XtalPi Leverage Molecular Dynamics to Enhance Small-Molecule Crystallization
•
German pharmaceutical giant Merck (NYSE: MRK) and China-based drug discovery solutions specialist XtalPi have published a study demonstrating the application of molecular dynamics (MD) simulations to guide small-molecule crystallization experiments. This innovative approach aims to achieve crystal shapes that facilitate crystallography data collection throughout the drug development process. Case Study:…
-
Neurophth Biotechnology Receives NMPA Approval for Phase I/II Gene Therapy Study
•
Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Sino-US multi-center Phase I/II study. The study will assess the safety, efficacy, and tolerability of its gene therapy NFS-02 (rAAV2-ND1) for ND1…
-
Shenzhen Core Medical Technology Secures RMB 200 Million in Series C+ Financing for Artificial Heart Tech
•
Shenzhen Core Medical Technology Co., Ltd, a leading Chinese manufacturer of artificial hearts, has reportedly raised nearly RMB 200 million (USD 29.1 million) in a Series C+ financing round. The round was led by Loyal Valley Capital, with participation from Greenwoods Asset, highlighting the strong investor confidence in Core Medtech’s…
-
Hainan Poly Pharm Wins Health Canada Approval for Generic Cytovene-IV (Ganciclovir)
•
Hainan Poly Pharm Co., Ltd (SHE: 300630), a China-based pharmaceutical company, has announced that it has received marketing approval from Health Canada for its generic version of Roche’s Cytovene-IV (ganciclovir). This development marks a significant step for the company as it expands its international footprint in the generic drugs market.…
-
Zephyrm Bioscience Secures Over RMB 200 Million in Series B Financing for Stem-Cell Drug Development
•
Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more than RMB 200 million (USD 29.1 million) in a Series B financing round. This significant investment, led by CCB Trust, will fuel the company’s efforts in advancing stem-cell drugs for a variety of diseases and…
